Completed
ROLOCOROsuvastatin LOading and Clinical Outcomes Trial
What is being tested
Rosuvastatin
Drug
Who is being recruted
Arterial Occlusive Diseases+2
+ Arteriosclerosis
+ Cardiovascular Diseases
Over 18 Years
+9 Eligibility Criteria
How is the trial designed
Treatment Study
Phase 3
Interventional
Study Start: January 2008
Summary
Principal SponsorYuksek Ihtisas Hospital
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner
Study start date: January 1, 2008
Actual date on which the first participant was enrolled.The aim of the present study was to evaluate the effect of pre-procedural single high loading dose (40 mg) of rosuvastatin on the primary end-points of all cause mortality and composite of death or myocardial infarction from cardiovascular (CV) causes, target vessel revascularization (TVR), or stroke.
Official TitleROsuvastatin LOading and Clinical Outcomes Trial
Principal SponsorYuksek Ihtisas Hospital
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Design Details
299 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Arterial Occlusive DiseasesArteriosclerosisCardiovascular DiseasesVascular DiseasesAtherosclerosis
Criteria
3 inclusion criteria required to participate
statin-naive patients
stable ischemic heart disease
de novo lesions appropriate for PCI
6 exclusion criteria prevent from participating
current statin use
statin allergic patients
acute coronary syndromes
lesions not appropriate for PCI
Show More Criteria
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.Treatment Groups
Study Objectives
One single intervention group is designated in this study
This study does not include a placebo group
Treatment Groups
Group I
Active ComparatorA 40 mg loading dose of rosuvastatin was administrated 24 h before the PCI.
Study Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
Suspended
CompletedOne Study Center